SOS1 and cancer: The clinical stage KRASG12C inhibitor, adagrasib,hasgarnered much attention recently based on its promising clinical activityacross several cancer types.3−5 Since adagrasib is an irreversibleinhibitor that targets GDP-loaded KRASG12C, we envisioneda combination strategy with an SOS1 binder that could disrupt theKRAS:SOS1 PPI and increase the concentration of adagrasib-susceptibleGDP-loaded KRASG12C, potentially leading to an increasedresponse rate and/or more durable clinical responses relative to singleagent adagrasib.